Dyne Therapeutics Appoints Vikram Karnani to Board of Directors

Core Insights - Dyne Therapeutics has appointed Vikram Karnani to its Board of Directors, bringing extensive experience in rare diseases and biopharmaceuticals [1][2] - The company is focused on advancing towards commercialization of its therapeutics for genetically driven neuromuscular diseases [1][4] Company Overview - Dyne Therapeutics is dedicated to delivering functional improvement for individuals with genetically driven neuromuscular diseases, developing therapeutics targeting muscle and the central nervous system [4] - The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), along with preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease [4] Leadership Insights - Vikram Karnani's background includes serving as CEO of Collegium Pharmaceutical and leading significant growth at Horizon Therapeutics, transforming it from $500 million to over $3 billion in revenue [2][3] - His expertise in launching products and driving growth is expected to enhance Dyne's strategy as it prepares for its first potential product launch in Q1 2027 [2][4]